Clinical Trial Update: Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of bosentan in sickle cell disease patients with pulmonary arterial hypertension was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Sickle Cell Disease

Drugs mentioned

• Bosentan (Bosentan)

Snippet

Sponsor: Actelion | Conditions: Pulmonary Hypertension | Phase 3 | Status: TERMINATED